Eugia Pharma Specialities, a wholly-owned subsidiary of Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804), has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Dasatinib Tablets, according to a Wednesday filing to the Indian stock exchanges.
The drug is bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company's reference listed drug Sprycel Tablets, which is indicated for treating chronic myelogenous leukemia and acute lymphoblastic leukemia.
The product is expected to be launched in the fiscal first quarter of financial year 2025-26.
The company's shares were up over 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.